BCL2 and neuroblastoma: More recently, several studies provided evidence that diverse expression profiles of the Bcl-2 family account for the heterogeneity of chemo-resistance in NB [167,168], implicating that individualized selection of small molecule inhibitors targeting to special anti-apoptotic Bcl-2 members may be important for treating chemo-resistant NB patients.